Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials肝活检评估的次优可靠性对随机临床试验的影响JOURNAL OF HEPATOLOGYIF332020-12-01266PREAI
MSDC-0602k, a New Oral Insulin Sensitizer in Insulin Resistant NASH Patients with and without Type 2 Diabetes (T2D)DIABETESIF7.52020-06-010PRE
Six month interim results of MSDC-0602 K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444)JOURNAL OF HEPATOLOGYIF332019-04-012PREAI
Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SRHEART RHYTHMIF5.72016-09-0126PREAI
A double-blind, randomized, parallel, placebo-controlled study examining the effect of cross-linked polyelectrolyte in heart failure patients with chronic kidney diseaseEUROPEAN JOURNAL OF HEART FAILUREIF10.82014-02-1817OAAI
CTST-21: A Phase 2, Randomized, Double-Blind, Multi-Center Study Comparing 15G Cross-Linked Polyelectrolyte (CLP) versus Placebo in Heart Failure Patients with Chronic Kidney DiseaseJOURNAL OF CARDIAC FAILUREIF8.22012-11-010PREAI
Pharmacokinetics (PK), safety, and pharmacodynamics (PD) of Hematide™ a synthetic peptide-based erythropoiesis stimulating agent (ESA), in a phase 1 single dose, dose escalating study in normal healthy volunteers (NHVS).CLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52006-02-010OAAI